Skip to main content
Barbara Deschler-Baier on Muck Rack

Barbara Deschler-Baier

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cancers | Free Full-Text | Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

|
By Filippo de Braud, Barbara Deschler-Baier, John Morris, Francis P. Worden
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

|
By Carina Heydt, Bianca van Veggel, Sebastian Michels, Barbara Deschler-Baier
| ascopubs.org
Treatment with selective early-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has demonstrated high efficacy in patients with lung cancer harboring activating EGFR mutations.
Open in Who Shared Issue with article?

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch - npj Precision Oncology

|
By Barbara Deschler-Baier, Silke Appenzeller
| Nature Verified
Abstract This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6::RET fusion. A 56-year-old male with a history of multiple lines of systemic therapies exhibited marked clinical amelioration shortly after initiating selpercatinib within the LOXO-RET-17001 study (ClinicalTrials.gov ID: NCT03157128, first posted: 2017-05-17).
Open in Who Shared Issue with article?
See all 3 articles